A randomized clinical trial of lithium in multiple system atrophy

Journal of Neurology

Volumn 260, Issue 2, 2013, Pages 458-461

  Saccà, Francesco ^a   Marsili, Angela ^a   Quarantelli, Mario ^b   Brescia Morra, Vincenzo ^a   Brunetti, Arturo ^b   Carbone, Rosa ^a   Pane, Chiara ^a   Puorro, Giorgia ^a   Russo, Cinzia Valeria ^a   Salvatore, Elena ^a   Tucci, Tecla ^a   De Michele, Giuseppe ^a   Filla, Alessandro ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Clinical trial; Lithium; Multiple system atrophy; Phase II; Safety

Indexed keywords

LITHIUM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHY DRAGER SYNDROME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ANTIMANIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84878834518     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6655-7     Document Type: Article

References (14)

1. Quinn N (1989) Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry (suppl):78-89
2. Sarkar S, Floto RA, Berger Z et al (2005) Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170:1101-1111
3. Webb JL, Ravikumar B, Atkins J et al (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009-25013
4. Sarkar S, Krishna G, Imarisio S et al (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17:170-178
5. Verstraete E, Veldink JH, Huisman MH et al (2012) Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 83:557-564
6. Al-Chalabi A, Shaw PJ, Young CA et al (2011) Protocol for a double-blind randomized placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) (Eudract number: 2008-006891-31). BMC Neurol 11:111
7. Miller RG, Moore DH, Forshew DA et al (2011) Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 77:973-979
8. Aggarwal SP, Zinman L, Simpson E et al (2010) Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:481-488
9. Forlenza OV, Diniz BS, Radanovic M et al (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351-356
10. Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 19:1391-1402
11. Beck AT, Steer RA, Brown GK et al (1996) BDI-II - beck depression inventory, 2nd edn. The Psychological Corporation Harcourt Brace and Company, San Antonio
12. Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670-676
13. Holmberg B, Johansson JO, Poewe W, Growth-Hormone MSA Study Group; European MSA Study Group et al (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22:1138-1144
14. Dodel R, Spottke A, Gerhard A et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11) C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25:97-107